Guided Therapeutics, Inc. Provides An Update On FDA Review Time For Luviva® Advanced Cervical Scan

NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the pre-market approval (PMA) application for the LuViva® Advanced Cervical Scan. The company has been in communication with the agency and is hoping to receive the agency’s decision within the next several weeks.

“We continue to believe our PMA amendment addressed the remaining questions the agency had and remain hopeful the FDA will find a pathway forward for LuViva,” said Gene Cartwright, Chief Executive Officer of Guided Therapeutics.

Help employers find you! Check out all the jobs and post your resume.

Back to news